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Narrative review of therapies for chronic enteropathies in dogs and cats
Abstract
Background The optimal medical treatment for chronic enteropathy (CE) in dogs and cats is controversial.
Sequential treatment using diet, antimicrobials, and immunosuppressive drugs is the most common strategy
used by clinicians.
Objectives To review the evidence for the effectiveness of dietary, drug, and alternative health interventions
for inducing clinical remission in dogs and cats with CE.
Animals Retrospective study of dogs and cats with a diagnosis of chronic enteropathy.
Methods MEDLINE and Centre for Agriculture and Bioscience International (CABI) databases (1950 to
March 2017) were searched for randomized controlled trials (RCTs), observational studies, and case series.
The primary outcome was induction of clinical remission. All studies were evaluated using the quality of
evidence grading guidelines (I‐IV), which assign a score defining the strength and quality of the evidence.
Results Twenty‐two studies (11 RCTs in dogs and 2 in cats and 9 cohort studies or case series) met the
inclusion criteria for inducing remission of gastrointestinal (GI) signs. Of the 13 RCTs achieving grade I
scores, 10 studies (totaling 218 dogs and 65 cats) compared single treatment: diet (n = 3),
immunosuppressives (n = 3), antimicrobials (n = 2), anti‐inflammatory drugs (n = 1), and probiotics (n = 1).
Three case series (grade III) reported clinical remission using an elimination diet fed to 55 cats and use of
enrofloxacin to induce remission in dogs with granulomatous colitis (2 studies totaling 16 dogs).
Conclusions and Clinical Importance The current evidence for treatment of CE is much greater in dogs
than in cats. There is sufficient strong evidence to recommend the use of therapeutic GI diets, glucocorticoids,
enrofloxacin, or some combination of these in dogs with CE. Therapeutic GI diets and glucocorticoids are
most useful in cats with CE.
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Background: The optimal medical treatment for chronic enteropathy (CE) in dogs and cats is
controversial. Sequential treatment using diet, antimicrobials, and immunosuppressive drugs is
the most common strategy used by clinicians.
Objectives: To review the evidence for the effectiveness of dietary, drug, and alternative health
interventions for inducing clinical remission in dogs and cats with CE.
Animals: Retrospective study of dogs and cats with a diagnosis of chronic enteropathy.
Methods: MEDLINE and Centre for Agriculture and Bioscience International (CABI) databases
(1950 to March 2017) were searched for randomized controlled trials (RCTs), observational
studies, and case series. The primary outcome was induction of clinical remission. All studies
were evaluated using the quality of evidence grading guidelines (I-IV), which assign a score
defining the strength and quality of the evidence.
Results: Twenty-two studies (11 RCTs in dogs and 2 in cats and 9 cohort studies or case series)
met the inclusion criteria for inducing remission of gastrointestinal (GI) signs. Of the 13 RCTs
achieving grade I scores, 10 studies (totaling 218 dogs and 65 cats) compared single treatment:
diet (n = 3), immunosuppressives (n = 3), antimicrobials (n = 2), anti-inflammatory drugs (n = 1),
and probiotics (n = 1). Three case series (grade III) reported clinical remission using an elimina-
tion diet fed to 55 cats and use of enrofloxacin to induce remission in dogs with granulomatous
colitis (2 studies totaling 16 dogs).
Conclusions and Clinical Importance: The current evidence for treatment of CE is much greater
in dogs than in cats. There is sufficient strong evidence to recommend the use of therapeutic GI
diets, glucocorticoids, enrofloxacin, or some combination of these in dogs with CE. Therapeutic
GI diets and glucocorticoids are most useful in cats with CE.
KEYWORDS
antibiotics, cyclosporine, diet, drug treatment, immunosuppressives, inflammatory bowel
disease, prednisone, quality of evidence guidelines, randomized controlled trial
1 | INTRODUCTION
Chronic enteropathies (CE) are a common cause for persistent or
recurrent gastrointestinal (GI) signs in dogs and cats. Although the
different forms of CE, including food-responsive enteropathy
(FRE),1,2 antimicrobial-responsive diarrhea (ARD),3 and corticosteroid
or immunosuppressive-responsive inflammatory bowel disease (IBD)
(steroid-responsive disease, SRD)4,5 have different etiologies, clinical
signs often overlap and distinguishing among these disorders may be
Abbreviations: AIEC, adherent/invasive Escherichia coli; ARD, antibiotic respon-
sive enteropathy; CABI, Centre for Agriculture and Bioscience International; CE,
chronic enteropathy; CIBDAI, canine IBD activity index; CRP, C-reactive
protein; CS, chondroitin sulfate; CsA, cyclosporine A; EBM, evidence-based
medicine; EF, Enterococcus faecium; FCEAI, feline chronic enteropathy activity
index; FISH, fluorescence in situ hybridization; FMT, fecal microbiota transplant;
FRE, food-responsive enteropathy; GC, granulomatous colitis; GI, gastrointesti-
nal; GOS, galacto-oligosaccharide; IBD, inflammatory bowel disease; MET,
metronidazole; PLE, protein losing enteropathy; RCT, randomized controlled
trial; SRD, steroid-responsive disease; TJP, tight junction protein.
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difficult, even with GI endoscopy and histopathologic review of
mucosal biopsy specimens. Alternatively, the different phenotypes of
CE might reflect a single disease process of increasing severity
affecting the intestinal immune system and selectively responsive to
different interventions over time. A prevailing hypothesis is that most
forms of CE involve a complex interplay among host genetics, the intes-
tinal microenvironment (primarily bacteria and dietary constituents), and
the immune system.6 Accordingly, sequential treatment using specially
formulated diets, antimicrobials, and immunosuppressive drugs is the
most common strategy used to achieve clinical remission, with a final
diagnosis often made in response to treatment, histopathologic evalua-
tion of intestinal biopsy specimens, or both.
Over the past 3 decades, many therapeutic interventions have
been developed for CE in dogs and cats, but scientific evidence of
efficacy and effectiveness often is lacking or highly variable. Still
other published studies are small (and often underpowered), and
very few properly designed clinical trials have been performed.
Evidence-based medicine (EBM) has emerged in different veterinary
disciplines to aid in clinical decision-making regarding patient
care.7–10 It has been defined as the integration of the best research
evidence with clinical expertise and owner and clinician preferences.
The basic tenet of EBM is that integration of these elements (ie, rel-
evant clinical research, clinical expertise, patient and owner prefer-
ences, and available resources) will result in the formation of
diagnostic and therapeutic plans that optimize clinical outcome and
quality of life.11
The purpose of this narrative review based on an extensive lit-
erature search was to examine the evidence regarding clinical effi-
cacy and effectiveness of dietary, drug, and alternative or
complementary treatments for inducing remission in dogs and cats
with CE. We first performed a structured and reproducible search
for RCTs and cohort studies and used expert opinion (Albert E.
Jergens and Kelly Makielski as experienced board-certified internists
and Annette O'Connor and Jonah Cullen as clinical epidemiologists)
to identify relevant case series and then evaluated the quality of
the intervention using quality of evidence grading guidelines.12
2 | MATERIALS AND METHODS
2.1 | Search strategy
The search strategy was developed to identify veterinary studies that
assessed dietary, drug, and alternative or complementary health inter-
ventions for CE in dogs and cats indexed in the MEDLINE and Centre
for Agriculture and Bioscience International (CABI) databases through
March 2017. The MEDLINE and CABI databases were accessed via
Web of Science through Iowa State University. Identical search terms
for each database included the following as text words and medical
subject headings: canine, dog, feline, cat, inflammatory bowel disease
(IBD), colitis, enterocolitis, and CE. Only publications written in English
that included an abstract were considered. In addition, the reference
lists of relevant articles were searched for other appropriate articles,
and clinician experts in gastroenterology were consulted to identify
additional studies.
2.2 | Study selection
For the electronic search, studies that used a comparison group were
considered relevant (ie, controlled clinical trials reporting the effect of
various treatments on clinical remission, cohort studies, and case-control
studies). Studies must also have provided a minimum treatment duration
of 14 days, must have contained a description of how clinical remission
was defined, and must have included histopathologic confirmation of
intestinal inflammation if a diagnosis of IBD was made. A single reviewer
(Kelly Makielski) assessed the eligibility of these studies, after a training
to ensure high agreement with the expert about relevant studies.
In addition to the structured search, a nonstructured search was
conducted for non-peer-reviewed articles (eg, scientific proceedings
from major veterinary meetings), review papers, and some expert opin-
ion papers. Two reviewers (Kelly Makielski and Jonah Cullen) indepen-
dently conducted an initial screen of abstracts for eligibility of these
sources and evaluated the full-text articles of identified abstracts for
final eligibility. The nonstructured search did not limit relevant studies
to those with a comparison group (ie, case series were included).
2.3 | Data extraction and quality assessment
For all relevant studies identified by the structured and nonstructured
search, 2 reviewers (Kelly Makielski and Albert E. Jergens) performed
data extraction and assigned an evidence grade based on the study
design. Extracted data included study treatment characteristics, partic-
ipant characteristics, and outcomes. All studies were evaluated using
the quality of evidence grading guidelines, which assign a score defin-
ing the strength and quality of the evidence.12 This tool previously
has been applied to establish EBM recommendations regarding veteri-
nary nutrition and nephrology.8,11,12 These guidelines categorize the
quality of evidence into grades I-IV, based on the applicability to clini-
cal case management (Table 1). Grades I and II are evidence of the
highest quality, whereas grade IV evidence is of the lowest quality.
The quality and strength of the evidence then can be used to make a
recommendation about the use of a specific treatment intervention.
2.4 | Summation of evidence
The corresponding author (Albert E. Jergens) compiled the data and sum-
marized the findings by treatment options and evidence grade of the rele-
vant studies. For each treatment, a summary of the findings was provided
for the available relevant study by evidence grade. The recommendations
were developed based on the opinion of the 2 clinical authors after
reviewing the literature (Albert E. Jergens and Kelly Makielski).
3 | RESULTS
3.1 | Eligible studies
The combined (structured and nonstructured) search strategy identified
1112 canine and 486 feline citations. The original search was conducted
in 2015, and then a second search was performed from November-
December 2016 through March 2017. Figures 1 and 2 show the flow-
charts of the selection of retrieved studies from both searches. Thirteen
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RCTs (11 in dogs, 2 in cats) were considered relevant. For the specific
treatments in which few or no RCTs were available, the best available
evidence was described, resulting in the description of an additional
9 cohort studies and case series. The quality of these selected studies
was moderate (grade III), and clinical outcome was considered impactful
because they demonstrated innovative treatment strategies that pro-
moted positive patient outcome.
3.2 | Diet as primary and adjuvant treatment for CE
Adverse reactions to food are a common cause for GI signs through
immunologic (ie, dietary sensitivity triggered by aberrant immune
responses) and nonimmunologic (including food intolerance and dietary
indiscretion) mechanisms.13 Clinical studies attest to the central role
that diet plays in management of dogs and cats with CE (Table 2).
3.2.1 | Grade I evidence studies
In 1 RCT, 26 dogs with small intestinal diarrhea randomized in a 2 : 1
ratio to be fed either a diet containing hydrolyzed soy protein (test
diet) or an intestinal diet containing proteins from a variety of
sources.14 Outcome measures included subjective response to treat-
ment, change in body weight, and disease activity using the canine IBD
activity index (CIBDAI) score. The short-term (3 months) response was
88% in both groups, however, only 1 in 6 dogs fed the intestinal diet
versus 13 of 14 dogs fed the hydrolysate diet maintained clinical remis-
sion over a 3-year period. For the final examination (median treatment
FIGURE 1 Literature search flowchart for canine CE
TABLE 1 Quality of evidence grading guidelines
Abbreviation: RCT, randomized controlled trial.
Adapted from Roudebush et al, 2004.
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duration of 1284 days), body weight and CIBDAI scores were unavail-
able for comparison among cohorts of dogs.
Results of 2 RCT evaluating the effect of diet in cats with CE have
been reported. In 1 randomized, double-blinded clinical trial, 55 pet
cats with chronic diarrhea were randomized to receive either a low-
fat (10%) or high-fat (23%) diet fed exclusively for 6 weeks as a pri-
mary intervention.15 Clients were instructed to record fecal scores
and the occurrence of vomiting episodes weekly, with the results ana-
lyzed between groups at 0, 1, 3, and 6 weeks. Results indicated that
there was no difference in clinical responses between test diets, with
fecal scores improving as early as 1 week and with maximal improve-
ment at 3 weeks. In the 2nd RCT, the efficacy of a hydrolyzed soya
diet was assessed in 10 cats with CE.16 Cats were randomized on
entry to be fed either a hydrolyzed soya protein diet or a commercial
prescription intestinal diet. A positive clinical response was defined as
cessation of GI signs. The use of the hydrolyzed soy-based diet
resolved GI signs in 7 of 10 cats versus 3 of 10 cats who fed the pre-
scription diet over a 4-week trial period. Although different clinical
responses to dietary intervention were observed, the effect of the
hydrolyzed soy diet as compared to the prescription diet was not sta-
tistically different. Importantly, this observation may have been influ-
enced by the number of cats enrolled in the trial, which was too small
to detect a difference.
3.2.2 | Grade III evidence studies
In 1 cohort study, 39 of 65 (60%) dogs with FRE or IBD responded
when fed an antigen-restricted diet of salmon and rice for at least
10 days.1 The severity of clinical signs was scored by means of CIB-
DAI.5 The CIBDAI score decreased significantly after treatment in
both groups (in dogs with FRE, 74% moderate to severe before versus
8% after treatment; in dogs with IBD, 85% moderate to severe before
versus 32% after treatment).
TABLE 2 Characteristics of included studies—dietary interventions
Study Species
Inclusion
diagnosis
No. of
patients
Study
quality Intervention
Treatment
duration Outcome
Guilford et al, 20012 Feline CE 55 Grade III Elimination diet 3 y Elimination diet resolved GI signs in
27 of 55 (49%) cats
Luckschander et al, 20061 Canine FRE 39 Grade III Salmon + rice diet 10 d All dogs showed decreased
CIBDA post-treatment
Allenspach et al, 200734 Canine FRE 39/70 Grade III Elimination diet 3 y Elimination diet induced long-term
remission in dogs with FRE
Mandigers et al, 201014 Canine CE 18 Grade I Hydrolyzed protein
versus control diet
3 y Hydrolyzed diet superior to control
diet for long-term clinical remission
Jergens et al, 201018 Feline FRE 6 Grade III Elimination diet 3 wk All cats showed decreased FCEAI
scores post-treatment
Waly et al, 201016 Feline CE 10 Grade I Hydrolyzed soya diet 4 wk Hydrolyzed diet superior to control
diet for clinical remission
Laflamme et al, 201115 Feline CE 55 Grade I High-fat versus low-fat diet 6 wk No difference in treatment response
Allenspach, et al, 201617 Canine FRE 131/203 Grade III Elimination or
hydrolyzed diet
12 wk Outcome at 1 y best for dogs with
FRE versus dogs with ARD and SRD
Abbreviations: ARD, antimicrobial-responsive diarrhea; CE, chronic enteropathy; CIBDAI, canine IBD activity index; FCEAI, feline chronic enteropathy
activity index; FRE, food-responsive enteropathy; SRD, steroid/immunosuppressive-responsive disease.
FIGURE 2 Literature search flowchart for feline CE
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In a retrospective cohort study of short-term and long-term out-
come in 203 dogs with CE, outcomes of 131 dogs (64%) with FRE
were compared to 33 dogs (16%) treated with antimicrobials (ie, ARD)
and 39 dogs (19%) treated with immunosuppressive drugs (ie, SRD).17
Diets prescribed to dogs with FRE included an elimination diet (55%),
a hydrolyzed diet (44%), and a homemade diet. Dogs with FRE
showed significantly better outcome (decreased clinical activity score)
at 4-8 weeks after discharge than those with ARD, and at 6 months
to 1 year after discharge as compared to both ARD and SRD groups.
There was no difference in outcome in dogs with FRE who fed an
elimination diet or a hydrolyzed diet.
Another study2 reported the clinical response of 55 cats with clini-
cal signs of CE challenged with dietary elimination trials. In this descrip-
tive single-group cohort study, 49% of the enrolled cats having chronic
GI signs responded to dietary modification as the primary treatment
intervention. When fed 1 of 2 commercial selected diets, 16 (29%) of
the 55 cats with CE were diagnosed as food-sensitive. The GI signs of
another 11 cats (20%) resolved on the elimination diet but did not recur
after challenge with their original food. Clinical signs in the most food-
sensitive cats resolved quickly within 3-5 days on the elimination diet.
Food-sensitive cats most commonly showed adverse reactions to beef
and cereal grains, including wheat, corn, and barley.
In a separate prospective nonrandomized cohort study, 23 cats
with IBD (74%) or FRE (26%) responded completely to an elimination
dietary trial alone (FRE) or in combination with PO-administered pred-
nisolone (IBD).18 Clinical response in affected cats was assessed using
a combination of GI signs and laboratory markers (eg, feline CE activ-
ity index) to define remission.
3.2.3 | Summary
There is strong evidence from RCTs to support a recommendation to
feed elimination diets to dogs and cats with CE (grade I evidence).
Moreover, several other descriptive cohort studies and nonrando-
mized trials (grade III evidence) support a recommendation for dietary
trials in the short-term and long-term maintenance of clinical remis-
sion. Evidence supporting a recommendation for further limiting some
dietary ingredients (eg, selected proteins, cereal grains) in the manage-
ment of CE in cats is based on dietary elimination trials and controlled
clinical reports (grade III evidence). It is not possible to ascertain which
form of diet (eg, novel intact protein or hydrolysate) is most effective
in modulating GI signs in dogs and cats.
3.3 | Antimicrobials as primary and adjuvant
treatment for CE
Antimicrobials are often advocated as a principal component of sequen-
tial treatment (eg, diet, antimicrobials, corticosteroids, and then other
immunosuppressive drugs) for dogs and cats with CE. Antimicrobials
presumably are used to counter the effects of microbial dysbiosis which
may initiate and drive host inflammatory responses.19,20 Antimicrobial
trials using metronidazole or tylosin have shown efficacy in a subset of
animals diagnosed with CE (Table 3).21,22 Although numerous trials
report remission with the use of metronidazole in dogs and cats, the
antimicrobial often was combined with diet and other drugs (eg, gluco-
corticoids) confounding interpretation as to what portion of the clinical
response was attributable to the antimicrobial alone.
3.3.1 | Grade I evidence studies
Tylosin-responsive diarrhea (TRD) is described in dogs as a form of
ARD, which typically affects middle-aged, large-breed dogs causing
chronic or intermittent small or large intestinal diarrhea.3,22 In 1 RCT,
the effect of tylosin was investigated in 71 dogs with histories of
intermittent diarrhea previously responsive to tylosin administration.23
Using a placebo-controlled, randomized, double-blinded study design,
dogs were assigned in a 2 : 1 ratio to receive tylosin versus placebo
and followed over 2 months. Treatment outcome was evaluated as
the mean of fecal consistency scores assigned during the last 3 days
of the treatment period. Results indicate that 27 of 61 enrolled dogs
developed diarrhea during the study period with a greater percentage
(P < .05) of dogs that received tylosin (17/20, 85%) versus placebo
(2/7, 29%) having normal fecal consistency at study completion.
Another RCT compared the clinical efficacy of rifaximin (RIF) to
metronidazole (MET) for treatment of dogs with CE.24 All dogs
enrolled in the study had chronic GI signs and histopathologic lesions
of lymphocytic-plasmacytic intestinal inflammation suggestive of idio-
pathic IBD. Twenty-four dogs were randomized to receive either RIF
(n = 14 dogs) or MET (n = 10 dogs) for 21 days, with changes in
disease activity (CIBDAI) and serum C-reactive protein (CRP) concen-
trations measured at the end of the study period. Remission was
TABLE 3 Characteristics of included studies—antimicrobial interventions
Study Species
Inclusion
diagnosis
No. of
patients
Study
quality Intervention
Treatment
duration Outcome
Hostutler et al, 200426 Canine GC 9 Grade III Enrofloxacin 1 mo Enrofloxacin effective for remission
Mansfield et al, 200927 Canine GC 7 Grade III Enrofloxacin 2 wk Enrofloxacin effective for remission
Jergens et al, 201029 Canine IBD 54 Grade I MTZ + prednisone vs
prednisone
3 wk No difference in treatment response
Kilpinen et al, 201123 Canine CE 20 Grade I Tylosin 2 mo Tylosin superior to placebo for remission
Rossi et al, 201425 Canine IBD 20 Grade I MTZ + prednisone
vs probiotic
2 mo No difference in treatment response
Menozzi et al, 201624 Canine IBD 24 Grade I MTZ vs rifaximin 3 wk No difference in treatment response
Allenspach et al, 201617 Canine ARD 33/203 Grade III MTZ or tylosin 2 wk Outcome at 1 y best for dogs with
FRE vs dogs with ARD and SRD
Abbreviations: ARD, antimicrobial-responsive diarrhea; CE, chronic enteropathy; FRE, food-responsive enteropathy; GC, granulomatous colitis; IBD,
inflammatory bowel disease; MTZ, metronidazole; SRD, steroid/immunosuppressive-responsive disease.
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defined as a ≥75% decrease in the baseline CIBDAI score. Results
showed that treatment with RIF or MET decreased clinical disease
severity and serum CRP concentrations in both groups similarly. No
adverse effects were noted. Potential study limitations included the
small number of dogs evaluated and the possible contribution of
antiemetic drugs to improve CIBDAI scores.
Two other RCTs investigated the efficacy of MET in treating dogs
with IBD. In separate studies, the combination of MET and prednisone
was compared to either prednisone alone or a multi-strain probiotic.25
In both trials, differences between treatments in the rate of clinical
remission (CIBDAI) were not observed. Additional details of these sep-
arate trials are included below.
3.3.2 | Grade III evidence studies
In an early descriptive single-group cohort study, the responsiveness of
histopathologic GC in 9 dogs (8 Boxer dogs and 1 English Bulldog) trea-
ted with enrofloxacin alone or in combination with MET and amoxicillin
was evaluated.26 Clinical signs, including diarrhea, resolved in all 9 dogs
within 12 days after beginning enrofloxacin alone or in combination
with either MET or amoxicillin and MET. Five dogs that underwent
repeat colonic biopsy showed marked histopathologic improvement
characterized by a decrease in the numbers of PAS-positive macro-
phages in biopsy specimens. All 9 dogs were free of clinical signs up to
21 months after treatment, and medications were discontinued in
3 dogs with resolution of clinical signs for up to 14 months.
A 2nd descriptive single-group cohort on GC in dogs investigated
the association between eradication of mucosal adherent/invasive
Escherichia coli (AIEC) and clinical remission with antimicrobial treat-
ment.27 Colonic biopsy specimens obtained in 7 Boxer dogs with GC
were evaluated for their content of AIEC before and after treatment
with enrofloxacin. Clinical response was observed in all 7 dogs within
2 weeks of antimicrobial treatment. Furthermore, fluorescence in situ
hybridization (FISH) was negative for AIEC in 4 of 5 dogs after enro-
floxacin treatment. Escherichia coli resistance to enrofloxacin was pre-
sent in the FISH-positive dog that relapsed.
A single study describing long-term outcome of dogs with CE
reports successful use of tylosin or MET to treat ARD.17
3.3.3 | Summary
There is evidence from a single RCT (grade I evidence) to support a
weak recommendation to use tylosin in treatment of ARD in dogs. The
recommendation is weak because not all dogs developed diarrhea dur-
ing the treatment period, decreasing the anticipated distribution of dogs
in both treatment groups. There is no strong evidence to support the
use of MET as a component of combination treatment for treatment of
dogs with IBD. The clinical response of Boxer dogs with GC to antimi-
crobial regimens containing enrofloxacin suggests an infectious cause
(eg, AIEC) for the inflammatory process (grade III evidence).
3.4 | Immunosuppressive drugs as primary and
adjuvant treatment for CE
Chronic enteropathy nonresponsive to diet and antimicrobial interven-
tions often are designated as idiopathic IBD, which is confirmed by
intestinal biopsy results showing mucosal inflammation. In these
instances, treatment typically requires immunosuppressive drugs, with
glucocorticoids being a mainstay of most treatment regimens
(Table 4).19 Immunosuppressive drug treatment also may include admin-
istration of other drugs, especially when adverse effects of corticoste-
roids are present or when animals fail to respond adequately to
systemic corticosteroids.28
3.4.1 | Grade I evidence studies
One RCT compared the efficacy of prednisone versus prednisone and
MET in induction therapy for dogs with IBD.29 Fifty-four dogs with
TABLE 4 Characteristics of included studies—steroid/immunosuppressive drug interventions
Study Species
Inclusion
diagnosis
No. of
patients
Study
quality Intervention
Treatment
duration Outcome
Allenspach et al, 200633 Canine IBD 14 Grade III Cyclosporine for steroid
refractory disease
10 wk 12 of 14 dogs show clinical remission
Allenspach et al, 200734 Canine IBD/PLE 18/70 Grade III Prednisolone first then
cyclosporine for steroid
refractory disease
10 wk for
prednisolone;
10 wk for CsA
10 of 21 dogs with IBD respond
to prednisolone; 2 of 8 dogs
respond to CsA; 7 of 10 dogs
with PLE respond to CsA
Jergens et al, 201029 Canine IBD 54 Grade I MTZ + prednisone vs
prednisone
3 wk No difference in treatment response
Jergens et al, 201018 Feline IBD 17 Grade III Prednisolone 3 wk All cats showed decreased FCEAI
scores post-treatment
Heilmann et al, 201230 Canine IBD 34 Grade I MTZ + prednisone vs
prednisone
3 wk Prednisone " serum cCP
Dye et al, 201331 Canine IBD 34 Grade I Prednisone vs budesonide 6 wk Prednisone is as effective
as budesonide for remission
Allenspach et al, 201617 Canine SRD 39/203 Grade III Combination of
prednisolone, CsA,
and/or azathioprine
Not stated Outcome at 1 y best for dogs
with FRE versus dogs
with ARD and SRD
White et al, 201739 Canine IBD 26 Grade I Prednisone + diet (ST)
versus ST + probiotic
8 wk No difference in treatment response
Abbreviations: ARD, antimicrobial-responsive diarrhea; cCP, canine calprotectin; CsA, cyclosporine A; FCEAI, feline chronic enteropathy activity
index; FRE, food-responsive enteropathy; IBD, inflammatory bowel disease; MTZ, metronidazole; SRD, steroid/immunosuppressive-responsive disease;
ST, standard IBD treatment (diet + prednisone).
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IBD were randomized to receive single or combination drug treatment
(CT) with clinical (CIBDAI) scores, and serum CRP concentrations
determined at diagnosis and after 21 days of drug treatment. Results
indicated that the rates of remission (>80%) were similar in both treat-
ment groups. Both treatments decreased CRP in comparison with pre-
treatment concentrations. In a related study, dogs from this earlier
RCT were shown to have increased serum calprotectin concentrations
compared with those of control dogs.30 Although results indicated
that measurement of serum calprotectin concentration was useful for
the detection of baseline inflammation, treatment with glucocorticoids
resulted in increased serum calprotectin concentrations despite clini-
cal remission.
A separate double-blinded RCT compared budesonide and pred-
nisone for induction therapy of IBD in dogs.31 Forty dogs with IBD
were randomized to receive budesonide or prednisone administered
daily for 6 weeks with remission rates (>75% reduction in baseline
CIBDAI after treatment) and adverse effects serving as outcome mea-
sures. Differences in remission rates were not observed between the
treatment groups. The frequency and severity of adverse effects
reported by pet owners were similar for the 2 treatment groups.
3.4.2 | Grade III evidence studies
Although most dogs with IBD respond to immunosuppressive doses
of corticosteroids, a subset of animals will not respond initially to
induction or will relapse after months of treatment.17,32 Separate
studies have investigated the efficacy of cyclosporine A (CsA) as a
single-agent treatment for steroid-refractory IBD in dogs. In a single-
group descriptive cohort, 14 dogs with IBD treated previously with
prednisolone for up to 2 years with minimal clinical response were
treated with CsA once daily for 10 weeks.33 Outcome measures
included clinical disease activity (CIBDAI score) and histopathology
score. Results indicated significant clinical improvement in 12 of
14 dogs with IBD and decreased numbers of intestinal mucosal cellu-
lar infiltrates (eg, CD3+ T cells) after CsA treatment. Another descrip-
tive cohort study investigated CsA as treatment in 8 dogs with IBD
that failed to respond to glucocorticoid treatment.34 These dogs
underwent the same treatment protocol as described above and were
evaluated using similar clinical and histopathologic indices of inflam-
mation. Long-term follow-up showed that 2 of 8 dogs with IBD and
7 of 10 dogs with PLE responded favorably to CsA treatment and
were rescued from euthanasia.
3.4.3 | Summary
Several RCTs provide high-quality evidence to support a recommen-
dation to administer glucocorticoids as induction treatment to dogs
with idiopathic IBD. Separate trials show that single-drug treatment
with prednisone is as efficacious as treatment with budesonide alone
or prednisone combined with MET. A single prospective cohort study
indicates that prednisolone treatment is effective in cats with IBD
(grade III evidence).18 Evidence supporting a recommendation for use
of CsA in dogs with steroid-refractory IBD is based on several, small
descriptive cohort studies (grade III evidence).
3.5 | Alternative/complementary therapies as
primary and adjuvant treatment for CE
The most commonly prescribed treatments for dogs and cats with CE
are directed toward suppressing the overactive immune responses
causing chronic GI signs. However, there is an important role for
nonimmunosuppressive therapies that may decrease mucosal inflam-
mation, counter microbial dysbiosis, and promote a more favorable
risk-benefit profile in patients.35 This need has prompted clinical
evaluation of several alternative/complementary treatments including
probiotics, prebiotics, and synbiotics for treatment of CE (Table 5).
3.5.1 | Grade I evidence studies
Probiotics, defined as bacteria with beneficial effects on the host,
have broad appeal to clinicians and clients wishing to use “natural”
therapeutic approaches. In an open-label trial,25 the efficacy of a
multi-strain probiotic (VSL#3) was investigated for treatment of IBD
in dogs. After IBD diagnosis, 20 dogs were randomized to receive
treatment with a multi-strain probiotic (n = 10) or combination drug
TABLE 5 Characteristics of included studies—Complementary/alternative treatment interventions
Study Species
Inclusion
diagnosis
No. of
patients
Study
quality Intervention
Treatment
duration Outcome
Rossi et al, 201425 Canine IBD 20 Grade I MTZ + prednisone vs
probiotic
2 mo No difference in treatment
response
Schmitz et al, 201543 Canine CE 12 Grade I Hydrolyzed diet + synbiotic
(EF + FOS) or placebo
6 wk No difference in treatment
for inflammasome gene
expression
Schmitz et al, 201542 Canine FRE 12 Grade I Hydrolyzed diet + synbiotic
(EF + FOS) or placebo
6 wk No difference in treatment
for intestinal cytokine
gene expression
Segarra et al, 201641 Canine IBD 19 Grade I Hydrolyzed diet +
chondroitin sulfate with
prebiotics or placebo
6 mo No difference in treatment
response
White et al, 201739 Canine IBD 26 Grade I Prednisone + diet (ST) vs
ST + probiotic
8 wk No difference in treatment
response
Webb et al, 201544 Feline CE but no histology 14 Grade IV Mesenchymal stem cells
(MSCs) or placebo IV
2 wk 5 of 7 MSC-treated cats
showed clinical
improvement
Abbreviations: CE, chronic enteropathy; EF, Enterococcus faecium; FOS, fructo-oligosaccharides; FRE, food-responsive enteropathy; IBD, inflammatory
bowel disease; MSC, mesenchymal stem cell; ST = standard IBD treatment (diet + prednisone).
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(prednisone + MET) treatment (n = 10) given daily for 8 weeks. Out-
comes included disease activity (CIBDAI score), histologic indices, epi-
thelial tight junction protein (TJP) expression, and fecal microbiota
composition. During the short course (8 weeks) of the study, clinical
signs of GI disease resolved in dogs of both treatment groups.
Although treatment with either probiotic or drugs was associated with
clinical and histopathologic improvement, only the probiotic was
shown to upregulate the expression of TJP in the intestines of dogs
with IBD. The increased expression of TJPs in these dogs might sug-
gest enhanced epithelial barrier integrity associated with probiotic
treatment.36–38
A separate RCT investigated the effects of a multi-strain probiotic
on the mucosal microbiota in dogs with IBD.39 Thirty-four dogs with
IBD were randomized to receive standard treatment (ie, elimination
diet + prednisone) with or without probiotic. Tissue sections from
endoscopic biopsy specimens were evaluated for mucosal bacteria
using FISH on a quantifiable basis. Disease activity (CIBDAI scores)
and changes in mucosal microbiota and TJP expression were assessed
before and after 8 weeks of IBD treatment. Both treatments
increased the numbers of total bacteria and individual species residing
within adherent mucus in a similar fashion. Although both treatments
were associated with rapid and progressive clinical remission, signifi-
cant improvement in histopathologic inflammation was not observed
in either group. Similar to the earlier clinical trial, epithelial TJP expres-
sion was increased in probiotic-treated dogs.
The effect of galacto-oligosaccharides (GOS) on the fecal micro-
biota of healthy cats and cats with IBD recently has been evaluated
during a randomized, double-blind, crossover feeding study.40 A GOS-
supplemented diet was fed to control cats and cats with IBD for a
period of 3 weeks with fecal microbiota evaluated using an 8-probe
FISH array. Overall, inter-animal variation of microbial composition
was high. Although a trend for increased Bifidobacterium spp. was
seen with GOS supplementation, it was not statistically significant in
either the healthy cats or cats with IBD. The low number of animals
enrolled coupled with extensive inter-animal variation in microbiota
limited the statistical power of our study.
Another RCT investigated the long-term management (180 days)
of dogs with IBD using a supplement containing chondroitin sulfate
and prebiotics (ie, resistant starch, β-glucans, and manno-oligosaccha-
rides) combined with a hydrolyzed diet.41 End points included clinical
signs, intestinal histopathology, fecal microbiota, and serum bio-
markers of inflammation and oxidative stress. Final data analysis (sup-
plement: n = 9 dogs; placebo: n = 10 dogs) indicated no differences
between groups at any time point for CIBDAI score, histopathologic
lesions, and fecal microbiota. Although results suggested favorable
alterations in selected serum biomarkers in response to supplement
administration, the sample size was small and the study was likely
underpowered.
One RCT has investigated the clinical efficacy of PO prebiotics in
combination with probiotics (synbiotic) in dogs with CE.42 Dogs diag-
nosed with CE were prospectively recruited to receive a hydrolyzed
elimination diet plus either a synbiotic product containing Enterococcus
faecium (EF) or placebo for 6 weeks. Of the 45 dogs recruited, 12 fin-
ished the clinical trial with 7 dogs treated with synbiotic and 5 dogs
treated with placebo. There was no difference between groups or
treatments regarding clinical efficacy, histology, or expression of any
inflammatory genes. Because the study was underpowered, it was not
possible to determine whether EF had a beneficial effect within the time
of 6 weeks. A 2nd RCT, using the same synbiotic and a hydrolyzed anti-
gen diet, showed no difference in inflammasome-related gene expres-
sion in 12 dogs undergoing treatment for chronic FRE.43
3.5.2 | Grade IV evidence studies
Stem cell therapy in cats with CE recently has been reported in a small
proof-of-concept study.44 Mesenchymal stem cells (MSCs) have been
shown to alter host responses and decrease inflammation in humans
by changes in cytokine secretion; direct interactions with T cells,
natural killer cells, neutrophils, and dendritic cells; and, by increasing
numbers of regulatory T cells.45–48 In this single report, allogenic
adipose-derived feline MSCs (fMSCs) were used to treat 7 cats with
chronic diarrhea (>6 months duration), whereas 4 cats with similar GI
signs received placebo in a blinded fashion. Study objectives included
determination of the safety and efficacy of stem cell therapy using a
client questionnaire. Owner responses were tabulated before and
2 weeks after the second of 2 fMSC or placebo treatments. No
adverse effects were observed in the fMSC-treated cats. Owners of
5 of 7 fMSC-treated cats reported substantial improvement in or reso-
lution of GI signs. Owners of placebo-treated cats reported no change
or worsening of clinical signs. During the study, no change in diet,
supplements, or prescribed medications was performed or no
histopathologic diagnosis was required for study entry.
3.5.3 | Summary
There is grade I evidence from different RCTs that multi-strain probio-
tics modulate the expression of TJPs, which may positively affect intes-
tinal barrier function to decrease intestinal inflammation. However,
dogs in both trials25,39 also were fed an elimination diet, and it remains
possible that the beneficial clinical response was at least partially attrib-
utable to the dietary intervention. These different studies show variable
effects of probiotic treatment on mucosal histopathology before versus
after treatment when evaluated after 2 months of continuous treat-
ment. The efficacy and effectiveness of probiotics for maintenance of
long-term clinical remission of CE have not been reported. Separate
studies evaluating the treatment effects of either prebiotics or synbio-
tics for dogs and cats with CE are underpowered and therefore provide
no clinically relevant data to evaluate. A single report exists for use of
MSCs in cats with poorly defined CE (grade IV evidence).
4 | DISCUSSION
Our narrative review based on an extensive literature search compre-
hensively summarizes the available evidence regarding treatment of
CE in dogs and cats. A challenge in critical review of therapies for CE
in dogs is the overlapping features of the 3 major types (FRE, ARD,
and SRD), which makes it difficult to distinguish the different forms of
the disease except by response to treatment. Importantly, therapeutic
approaches are influenced by suspicion of a breed-related problem,
age of the patient, severity of GI signs, serum albumin and cobalamin
concentrations, endoscopic mucosal appearances, and the presence of
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histopathologic changes, such as the type and magnitude of cellular
infiltrate, the presence of mucosal bacteria, and architectural alter-
ations of villus atrophy, ulceration or erosions, lymphangiectasia, or
crypt abscesses, or some combination of these.49,50
Most clinicians favor treatment trials first, reserving endoscopy or
surgery to obtain intestinal biopsy specimens in poor-responder or
nonresponder patients and to confirm the presence and severity of
intestinal inflammation while eliminating other intestinal disorders
such as GI histoplasmosis and lymphoma.51 In several reports, dogs
with FRE were younger than dogs with SRD and most often pre-
sented with signs of large bowel disease.17,34 They also usually
showed low clinical disease activity and normal serum albumin con-
centrations as compared with dogs with ARD and SRD. Clinical
response to dietary change typically is rapid within 1-2 weeks of
changing the diet. If dietary trials with 2 different diets are unsuccess-
ful, then adjunct treatments along with diet should be attempted.
Dogs responding to antimicrobials usually are younger predominantly
large-breed dogs (German Shepherd dogs, Rough Collies, and Golden
Retrievers). Although short-term response to both MET and tylosin
have been observed in dogs with ARD, studies describing long-term
control of GI signs are few.17,23 The use of FISH to identify mucosal-
associated bacteria, such as AIEC found in Boxers and French Bull-
dogs with GC, may confirm the presence of an infectious agent and
the need for an antimicrobial trial. Generally speaking, dogs with SRD
are middle-aged or older and have a more severe clinical disease phe-
notype, abnormal serum albumin and cobalamin concentrations, endo-
scopic mucosal abnormalities, and variable degrees of histopathologic
(predominantly lymphocytic-plasmacytic cellular infiltrates) inflamma-
tion within intestinal biopsy specimens. Dogs having mild-to-
moderate disease often are treated using a step-up approach (ie, first
dietary trial, followed by antimicrobial trial, and then use of immuno-
suppressive drugs such as prednisone or prednisolone if inadequate or
failed prior responses are observed).51 For other dogs having
moderate-to-severe clinical disease, a step-down approach is used,
with concurrent treatment of diet, antimicrobials, and corticosteroids
or other immunosuppressive drugs given from the outset and then
withdrawing immunosuppressive drugs and antimicrobials in patients
with a favorable response.28
The retrieved literature yielded a few well-designed RCTs (dogs:
n = 11; cats: n = 2) involving dietary, antimicrobial, immunomodulatory,
or alternative or complementary treatments, with most interventions
targeting IBD. Of concern is the fact that several of the clinical studies
were small, underpowered investigations that yielded data of no or lim-
ited statistical significance.24,40–43 Therefore, we supplemented these
RCT data with cohort studies (ie, studies that follow dogs or cats over
an extended period of time to look for the development of the out-
come) to provide additional evidence-based appraisal of non-RCT
treatments.
There is strong evidence from RCTs to support a recommenda-
tion to feed elimination diets to dogs and cats with CE (grade I evi-
dence). Beyond the aforementioned RCTs, other EBM data in dogs
and cats utilizing a spectrum of controlled,52–55 elimination,1,2,4,18 and
hydrolyzed16,56 diets suggest that nutritional treatment for CE is over-
whelmingly beneficial. Moreover, 2 studies provide convincing evi-
dence of long-term (up to 3 years after intervention) clinical remission
in dogs with CE when fed antigen-restricted diets.14,17 Although the
overall response rate for dogs generally exceeds 50%, it is even
greater for cats regardless of whether the diet is used as a pri-
mary2,16,18 or adjunct4,18,53–55 intervention. The reason why some
patients do not relapse on rechallenge (if performed) with their origi-
nal diet is not fully known, and this strategy remains a trial-and-error
approach used by individual clinicians.
Considerations for drug selection with CE include drug class (glu-
cocorticoids, antibiotics, immunosuppressives), disease phenotype
(ARD, IBD, protein-losing enteropathy [PLE], steroid-refractory dis-
ease), treatment stage (induction therapy, maintenance therapy, flare,
refractory disease), and histopathologic lesions (lymphocytic-
plasmacytic enterocolitis, granulomatous colitis, intestinal lymphan-
giectasia). There is grade I evidence that most dogs with IBD respond
to single drug glucocorticoid for induction therapy of clinical dis-
ease.31 Studies evaluating long-term (over a 3-year period) control
using immunosuppressive drug protocols provide less convincing evi-
dence of remission success.17,32 Only sparse evidence (grade III evi-
dence) in few animals (n = 22) is available regarding the use of CsA
for treatment of steroid-refractory CE in dogs.33 Anecdotally, other
drugs including azathioprine, chlorambucil, leflunomide, and mycophe-
nolate have been used for treatment of CE in dogs and cats, but well-
designed studies have not been reported.
Protein losing enteropathy in dogs was not a specific form of CE
included in our review based on selection of our search terms. Rather,
we chose not to include studies with a diagnosis of primary intestinal
lymphangiectasia because treatment recommendations for this dis-
tinct form of PLE seem less arbitrary and primarily based on dietary
intervention with low-fat diets.57,58 However, several other studies
describe dogs with CE with PLE that have histopathologic lesions of
villus lacteal changes accompanied by lamina propria cellular inflam-
mation.34,48,49 In 1 descriptive cohort study, combination treatment
with chlorambucil + prednisolone versus azathioprine + prednisolone
was associated with better 6-month survival in dogs with CE compli-
cated by PLE.59
Antimicrobials have a legacy of use as empirical treatment in dogs
and cats with CE. Unfortunately, this historic use of antimicrobials has
relatively weak support by large, randomized, placebo-controlled tri-
als.23 Several small case series uphold a role (grade III evidence) for
enrofloxacin in treating GC in dogs.26,27 Studies providing support
(grade III evidence) for use of MET in cats with IBD are largely based
on results derived from 4 retrospective case series.4,53–55 Moreover,
complications from acute and chronic administration of antimicrobials
remain a clinical concern. For example, broad-spectrum antimicrobials
can cause GI signs including diarrhea,3 the emergence of enrofloxacin-
resistant AIEC is seen in some dogs with GC,27 and both MET60 and
tylosin61 have been associated with disturbances in the microbiome
of healthy dogs after antimicrobial administration. In addition, recent
epidemiological data in humans62 and dogs with infectious enteritis63
implicate exposure to antimicrobials as a risk factor for developing
IBD later in life for a subset of patients.
Complementary and alternative medicine is used increasingly by
humans with digestive disorders, including IBD and irritable bowel
syndrome.64 Some commonly used treatments include probiotics, pre-
biotics, fish oil, aloe vera, and turmeric (http://www.mayoclinic.org/
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diseases-conditions/inflammatory-bowel-disease/basics/alternative-
medicine/con-20034908). However, there are few well-designed
studies of their safety and efficacy in humans or dogs and cats. There
is evidence (grade I studies) from RCTs that multi-strain probiotics are
beneficial for induction of remission in dogs with IBD. As probiotic
effects are likely strain-specific, multi-strain products may be most
efficacious, but results of these studies should not be extrapolated to
different probiotics containing different bacterial strains.65 Notewor-
thy, there is clinical evidence that multi-strain probiotics increase the
expression of intestinal epithelial TJP, which may improve gut barrier
integrity when used with dietary treatment for disease remission.
Fecal microbiota transplantation (FMT) is another potential thera-
peutic option for nonresponsive CE, but only single case reports have
been published. There is a report of preliminary clinical and microbiome
assessment in a dog with refractory IBD and a cat with nonresponsive
CE after FMT.66 In this case series, fresh feces was administered by
enema to both patients, and the cat also received a fecal suspension
into the duodenum by endoscopic delivery. Fecal samples were col-
lected before and after FMT and evaluated for compositional alter-
ations using next-generation sequencing of 16S rRNA bacterial genes.
Post-FMT, fecal consistency rapidly (24 hours) improved in both recipi-
ents, and other GI signs were mostly attenuated. Fecal samples clus-
tered phylogenetically with the donors by day 2 but were decreased in
species richness over time after treatment. In a separate case series,
FMT was used in 8 dogs that had diarrhea associated with refractory
Clostridium perfringens infection.67 Donor feces was administered by
enema in all 8 dogs as an outpatient treatment. Results indicated that
FMT was successful in normalizing fecal character in all 8 dogs with
6 of the 8 dogs having negative post-FMT PCR panels for C. perfringens
alpha toxin gene expression. A recent report suggests clinical indications
and delivery techniques for FMT in dogs and cats with CE.68
Intestinal stem cells (ISCs) can be isolated and cultured in vitro
giving rise to 3-dimensional self-organizing structures termed orga-
noids.69 Organoids resemble the intestinal epithelium in vivo as they
possess crypt and villus regions that contain multiple cell types that
promote mucosal regeneration. Studies have shown that ISCs of mice,
humans, and other species are organized into intestinal organoids
under appropriate in vitro culture conditions.70–72 Intestinal organoids
derived from canine ISCs recently have been described and may offer
regenerative applications in the treatment of IBD and other forms of
CE in dogs.71,73 Successful transplantation of ISCs in experimental
colitis models demonstrates that they adhere to and become an inte-
grated part of the epithelium, thereby improving mucosal healing.
Lastly, canine ISCs offer a unique drug screening platform for per-
forming high-throughput efficacy and toxicity studies that translate
directly to pharmacologic studies in humans with CE.73
In summary, there are a few well-designed trials (RCT and
others) defining optimal treatment for dogs and cats with
CE. Current EBM treatment guidelines for CE are found in Table 6.
There is decidedly greater EBM data on treatment for CE in dogs
(examples of grade I evidence) as compared to cats with CE
(no evidence for grade I trials with less robust evidence for thera-
peutic recommendations). Treatments with the strongest evidence
supporting their efficacy should be recommended first with consider-
ations for financial resources and client preferences taken into
consideration. As noted by others, it would be erroneous to assume
that treatments supported by weaker forms of evidence may not be
beneficial in some patients with CE.11
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